Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental obesity technique can matter in a market dominated by giants. That’s a tough ...

Veru agreed to conduct a clinical study of one of its treatments in combination with Novo Nordisk's Wegovy weight loss drug. Under the terms of a supply agreement with Novo, Veru will conduct and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to indicate ...

Skye's obesity drug misses mid-stage trial main goal, shares tank Skye Bioscience's experimental treatment failed to achieve the main goal of significantly reducing weight in adults with obesity in a ...

TheStreet Pro is our premium subscription service. It offers everything you need to manage and grow your investments, including access to exclusive premium articles, TheStreet Pro's portfolio and ...